Inventiva announced an exclusive licencing agreement with Hepalys Pharma, aimed at the development and commercialisation of promising drug candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH) in the important markets of Japan and South Korea.
Under this exclusive licencing agreement, Inventiva will receive an upfront payment of $10 million. In addition to this initial sum, there is the potential for milestone payments, totalling up to $231 million, contingent upon successful progress in clinical development, regulatory approvals, and commercialisation efforts. Furthermore, tiered royalties will be received, ranging from the mid double digits to the low twenties, based on net sales of lanifibranor in Japan and South Korea.
This collaboration represents a significant milestone for Inventiva to expand its global footprint, reaching into the key markets of Japan and South Korea. This agreement, accelerates the potential commercialisation of lanifibranor in these two major territories. Moreover, this partnership remains committed to advancing lanifibranor as a potential solution for NASH patients in Japan and South Korea.
Lanifibranor is an orally-administered small molecule designed to induce a range of therapeutic effects in the body, including anti-fibrotic, anti-inflammatory, and beneficial changes in vascular and metabolic functions. It accomplishes these effects by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms. These PPARs are well-known nuclear receptor proteins responsible for regulating gene expression.
Unlike other PPAR agonists that selectively target one or two isoforms, lanifibranor's broad-spectrum activation offers a promising approach to comprehensively address the complex aspects of NASH and its associated complications.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!